The story continued beyond the concert with Visual Aid for Band Aid, Fashion Aid, Sport Aid, and then Live 8—the global series of benefit concerts featuring more than 1,000 musicians that ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.